Chronic Low-Level Arsenite Exposure through Drinking Water Increases Blood Pressure and Promotes Concentric Left Ventricular Hypertrophy in Female Mice

Toxicologic Pathology

Volumn 40, Issue 3, 2012, Pages 504-512

  Sanchez Soria, Pablo ^a   Broka, Derrick ^a   Monks, Sarah L ^a   Camenisch, Todd D ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

arsenic; cardiovascular system; concentric hypertrophy; environmental toxicology; heart; hypertension

Indexed keywords

ARSENITE SODIUM; ARSENOUS ACID DERIVATIVE; DRINKING WATER; SODIUM DERIVATIVE;

ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; CYTOCHEMISTRY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; STANDARD; TOXICITY TESTING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTERIAL WALL THICKNESS; CARDIOTOXICITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENVIRONMENTAL EXPOSURE; FLUID INTAKE; HEART LEFT VENTRICLE MASS; HISTOPATHOLOGY; LONG TERM EXPOSURE; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; ARSENITES; BLOOD PRESSURE; DRINKING WATER; ECHOCARDIOGRAPHY; FEMALE; HISTOCYTOCHEMISTRY; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MICE; SODIUM COMPOUNDS; TOXICITY TESTS, CHRONIC;

EID: 84861227234     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623311432297     Document Type: Article

References (37)

1. Abernathy C. O. Liu Y. P. Longfellow D. Aposhian H. V. Beck B. Fowler B. Goyer R. Menzer R. Rossman T. Thompson C. (1999). Arsenic: health effects, mechanisms of actions, and research issues. Environ Health Perspect 107, 593.
2. Bae O. N. Lim E. K. Lim K. M. Noh J. Y. Chung S. M. Lee M. Y. Yun Y. P. Kwon S. C. Lee J. H. Nah S. Y. (2008). Vascular smooth muscle dysfunction induced by monomethylarsonous acid (MMAIII): a contributing factor to arsenic-associated cardiovascular diseases. Environ Res 108, 300–8.
3. J.J.C., Bilszta, G.J., Dusting, F., Jiang, Arsenite increases vasoconstrictor reactivity in rat blood vessels: role of endothelial nitric oxide function, Int J Toxicol, (2006), 25, 303
4. Carmignani M. Boscolo P. Castellino N. (1985). Metabolic fate and cardiovascular effects of arsenic in rats and rabbits chronically exposed to trivalent and pentavalent arsenic. Arch Toxicol Suppl 8, 452–5.
5. Carretero O. A. Oparil S. (2000). Essential hypertension: Part I: definition and etiology. Circulation 101, 329–35.
6. Casale P. N. Devereux R. B. Milner M. Zullo G. Harshfield G. A. Pickering T. G. Laragh J. H. (1986). Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 105, 173.
7. Chang C. C. Ho S. C. Tsai S. S. Yang C. Y. (2004). Ischemic heart disease mortality reduction in an arseniasis-endemic area in southwestern Taiwan after a switch in the tap-water supply system. Journal of Toxicology and Environmental Health, Part A 67, 1353–61.
8. Chen C. J. Chiou H. Y. Chiang M. H. Lin L. J. Tai T. Y. (1996). Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol 16, 504.
9. Chen Y. Graziano J. H. Parvez F. Liu M. Slavkovich V. Kalra T. Argos M. Islam T. Ahmed A. Rakibuz-Zaman M. Hasan R. Sarwar G. Levy D. van Geen A. Ahsan H. (2011). Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study. BMJ 342, d2431.
10. Chen C. J. Hsueh Y. M. Lai M. S. Shyu M. P. Chen S. Y. Wu M. M. Kuo T. L. Tai T. Y. (1995). Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25, 53.
11. Chobanian A. V. Bakris G. L. Black H. R. Cushman W. C. Green L. A. Izzo J. L. Jr Jones D. W. Materson B. J. Oparil S. Wright J. T., Jr. (2003). Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42, 1206.
12. Ganau A. Devereux R. B. Roman M. J. de Simone G. Pickering T. G. Saba P. S. Vargiu P. Simongini I. Laragh J. H. (1992). Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19, 1550–8.
13. Grossman W. Jones D. McLaurin L. (1975). Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56, 56.
14. Hays A. M. Lantz R. C. Rodgers L. S. Sollome J. J. Vaillancourt R. R. Andrew A. S. Hamilton J. W. Camenisch T. D. (2008). Arsenic-induced decreases in the vascular matrix. Toxicol Pathol 36, 805.
15. Heron M. Hoyert D. L. Murphy S. L. Xu J. Kochanek K. D. Tejada-Vera B. (2009). Deaths: final data for 2006. Natl Vital Stat Rep 57, 1–134.
16. Koren M. J. Devereux R. B. Casale P. N. Savage D. D. Laragh J. H. (1991). Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114, 345–52.
17. Krege J. H. Hodgin J. B. Hagaman J. R. Smithies O. (1995). A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25, 1111.
18. Kumagai Y. Pi J. (2004). Molecular basis for arsenic-induced alteration in nitric oxide production and oxidative stress: implication of endothelial dysfunction. Toxicol Appl Pharmacol 198, 450–7.
19. Kwok R. K. Mendola P. Liu Z. Y. Savitz D. A. Heiss G. Ling H. L. Xia Y. Lobdell D. Zeng D. Thorp J. M., Jr (2007). Drinking water arsenic exposure and blood pressure in healthy women of reproductive age in Inner Mongolia, China. Toxicol Appl Pharmacol 222, 337–43.
20. Lee M. Y. Jung B. I. Chung S. M. Bae O. N. Lee J. Y. Park J. D. Yang J. S. Lee H. Chung J. H. (2003). Arsenic-induced dysfunction in relaxation of blood vessels. Environ Health Perspect 111, 513.
21. Lloyd-Jones D. Adams R. J. Brown T. M. Carnethon M. Dai S. De Simone G. Ferguson T. B. Ford E. Furie K. Gillespie C. (2010). Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation 121, e46.
22. Mandal B. K. Suzuki K. T. (2002). Arsenic round the world: a review. Talanta 58, 201–35.
23. Medrano M. J. Boix R. Pastor-Barriuso R. Palau M. Damian J. Ramis R. Del Barrio J. L. Navas-Acien A. (2010). Arsenic in public water supplies and cardiovascular mortality in Spain. Environ Res 110, 448–54.
24. C.C.L., Murray, A.D., Lopez, Mortality by cause for eight regions of the world: Global Burden of Disease Study, The Lancet, (1997), 349, 1269-1276
25. National Center for Health Statistics (2011). Health, United States, 2010: With Special Feature on Death and Dying. Hyattsville, MD.
26. Navas-Acien A. Sharrett A. R. Silbergeld E. K. Schwartz B. S. Nachman K. E. Burke T. A. Guallar E. (2005). Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am J Epidemiol 162, 1037.
27. Pollock D. M. Rekito A. (1998). Hypertensive response to chronic NO synthase inhibition is different in Sprague-Dawley rats from two suppliers. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 275, R1719.
28. Rahman M. Tondel M. Ahmad S. A. Chowdhury I. A. Faruquee M. H. Axelson O. (1999). Hypertension and arsenic exposure in Bangladesh. Hypertension 33, 74.
29. Sahn D. DeMaria A. Kisslo J. Weyman A. (1978). Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58, 1072.
30. Soucy N. V. Mayka D. Klei L. R. Nemec A. A. Bauer J. A. Barchowsky A. (2005). Neovascularization and angiogenic gene expression following chronic arsenic exposure in mice. Cardiovascular Toxicology 5, 29–41.
31. States J. C. Srivastava S. Chen Y. Barchowsky A. (2009). Arsenic and cardiovascular disease. Toxicological Sciences 107, 312–23.
32. Treasure C. B. Klein J. L. Vita J. A. Manoukian S. V. Renwick G. H. Selwyn A. P. Ganz P. Alexander R. W. (1993). Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 87, 86.
33. Tseng C. H. Chong C. K. Tseng C. P. Hsueh Y. M. Chiou H. Y. Tseng C. C. Chen C. J. (2003). Long-term arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in Taiwan. Toxicol Lett 137, 15–21.
34. U.S. Environmental Protection Agency (2001). National primary drinking water regulations; arsenic and clarifications to compliance and new source contaminants monitoring; final rule. Fed Reg 66, 6975–7066.
35. Verdecchia P. Schillaci G. Borgioni C. Ciucci A. Battistelli M. Bartoccini C. Santucci A. Santucci C. Reboldi G. Porcellati C. (1995). Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 25, 871–8.
36. Wu M. M. Chiou H. Y. Wang T. W. Hsueh Y. M. Wang I. H. Chen C. J. Lee T. C. (2001). Association of blood arsenic levels with increased reactive oxidants and decreased antioxidant capacity in a human population of northeastern Taiwan. Environ Health Perspect 109, 1011.
37. Yuan Y. Marshall G. Ferreccio C. Steinmaus C. Selvin S. Liaw J. Bates M. N. Smith A. H. (2007). Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed region II of Chile from 1950 to 2000. Am J Epidemiol 166, 1381.